Have a feature idea you'd love to see implemented?
Let us know!
IRD Opus Genetics Inc.
Price (delayed)
$1.26
Market cap
$39.78M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.09
Enterprise value
$3.14M
Highlights
The company's net income has shrunk by 195% YoY and by 93% QoQ
The company's EPS has shrunk by 175% YoY and by 102% QoQ
Key stats
What are the main financial stats of IRD
Market
Valuations
Earnings
Shares outstanding
31.57M
Market cap
$39.78M
Enterprise value
$3.14M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.96
Price to sales (P/S)
3.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.38
Revenue
$8.38M
Gross profit
$8.38M
Net income
-$27.19M
EBIT
-$27.19M
EBITDA
-$27.19M
Free cash flow
-$13.59M
Per share
Balance sheet
Liquidity
EPS
-$1.09
EPS diluted
-$1.09
Free cash flow per share
-$0.52
Book value per share
$1.31
Revenue per share
$0.32
TBVPS
$1.54
Total assets
$40.39M
Total liabilities
$6.09M
Debt
$0
Equity
$34.3M
Working capital
$34.3M
Debt to equity
0
Current ratio
6.63
Quick ratio
6.56
Net debt/EBITDA
1.35
Margins
Efficiency
Dividend
EBITDA margin
-324.4%
Gross margin
100%
Net margin
-324.4%
Operating margin
-351.7%
Return on assets
-56.9%
Return on equity
-63.6%
Return on invested capital
N/A
Return on capital employed
-79.3%
Return on sales
-324.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
IRD stock price
How has the Opus Genetics stock price performed over time
Intraday
5.88%
1 week
16.67%
1 month
9.57%
1 year
-58.96%
YTD
5.88%
QTD
5.88%
Financial performance
How have Opus Genetics's revenue and profit performed over time
Revenue
$8.38M
Gross profit
$8.38M
Operating income
-$29.47M
Net income
-$27.19M
Gross margin
100%
Net margin
-324.4%
The company's net income has shrunk by 195% YoY and by 93% QoQ
The operating income has plunged by 95% from the previous quarter
The revenue has dropped by 85% year-on-year and by 49% since the previous quarter
IRD's gross profit has shrunk by 85% YoY and by 49% QoQ
Growth
What is Opus Genetics's growth rate over time
Valuation
What is Opus Genetics stock price valuation
P/E
N/A
P/B
0.96
P/S
3.93
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.38
The company's EPS has shrunk by 175% YoY and by 102% QoQ
The P/B is 60% below the 5-year quarterly average of 2.3 and 17% below the last 4 quarters average of 1.1
Opus Genetics's equity has decreased by 32% YoY and by 16% QoQ
The revenue has dropped by 85% year-on-year and by 49% since the previous quarter
IRD's P/S is 20% above its last 4 quarters average of 3.1
Efficiency
How efficient is Opus Genetics business performance
Opus Genetics's return on equity has shrunk by 197% YoY and by 111% QoQ
IRD's ROA has plunged by 195% YoY and by 107% from the previous quarter
Dividends
What is IRD's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for IRD.
Financial health
How did Opus Genetics financials performed over time
The total liabilities has surged by 56% year-on-year and by 45% since the previous quarter
The current ratio has dropped by 52% year-on-year and by 38% since the previous quarter
Opus Genetics's debt is 100% lower than its equity
Opus Genetics's equity has decreased by 32% YoY and by 16% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.